Skip to main content
Erschienen in: Journal of Community Health 4/2022

25.03.2022 | COVID-19 | Original Paper Zur Zeit gratis

A SARS-CoV-2 Outbreak Among Nursing Home Residents Vaccinated with a Booster Dose of mRNA COVID-19 Vaccine

verfasst von: Giancarlo Ripabelli, Michela Lucia Sammarco, Giovanni Rezza, Antonio D’Amico, Roberta De Dona, Mariagrazia Iafigliola, Albino Parente, Nicandro Samprati, Arturo Santagata, Carmen Adesso, Anna Natale, Michela Anna Di Palma, Fabio Cannizzaro, Cosimo Dentizzi, Paola Stefanelli, Manuela Tamburro

Erschienen in: Journal of Community Health | Ausgabe 4/2022

Einloggen, um Zugang zu erhalten

Abstract

This study describes a SARS-CoV-2 outbreak caused by the Delta (B.1.617.2) variant in a nursing home in Central Italy during October–November 2021. Trained interviewers collected data from residents, staff, and administration officers with an agreed informed consent procedure. Thirty-two (44.5%) out of 72 residents (median age 89 years) and six (26.1%) of 23 healthcare workers were found to be infected with SARS-CoV-2. Infections occurred more often among residents with a higher index of independence in daily living activities, suggesting an increased risk for those with more interactions. Twenty-five infected residents (78.1%) received the booster dose of mRNA anti-COVID-19 vaccine > 7 days before SARS-CoV-2 onset. Half of the infected residents had mild symptoms, and only three required hospitalisation, one of whom died from COVID-19 complications. The study underlines the effectiveness of a booster dose in providing a high protection against severe disease and hospitalisation even among vulnerable individuals infected with the Delta variant of concern.
Literatur
3.
Zurück zum Zitat Lopez Bernal, J., Andrews, N., Gower, C., Gallagher, E., Simmons, R., Thelwall, S., Stowe, J., Tessier, E., Groves, N., Dabrera, G., Myers, R., Campbell, C. N. J., Amirthalingam, G., Edmunds, M., Zambon, M., Brown, K. E., Hopkins, S., Chand, M., & Ramsay, M. (2021). Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant. The New England Journal of Medicine, 385(7), 585–594. https://doi.org/10.1056/NEJMoa2108891CrossRefPubMed Lopez Bernal, J., Andrews, N., Gower, C., Gallagher, E., Simmons, R., Thelwall, S., Stowe, J., Tessier, E., Groves, N., Dabrera, G., Myers, R., Campbell, C. N. J., Amirthalingam, G., Edmunds, M., Zambon, M., Brown, K. E., Hopkins, S., Chand, M., & Ramsay, M. (2021). Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant. The New England Journal of Medicine, 385(7), 585–594. https://​doi.​org/​10.​1056/​NEJMoa2108891CrossRefPubMed
7.
Zurück zum Zitat Pouwels, K. B., Pritchard, E., Matthews, P. C., Stoesser, N., Eyre, D. W., Vihta, K.-D., House, T., Hay, J., Bell, J. I., Newton, J. N., Farrar, J., Crook, D., Cook, D., Rourke, E., Studley, R., Peto, T. E. A., Diamond, I., & Walker, A. S. (2021). Effect of delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. Nature Medicine, 27(12), 2127–2135. https://doi.org/10.1038/s41591-021-01548-7CrossRefPubMedPubMedCentral Pouwels, K. B., Pritchard, E., Matthews, P. C., Stoesser, N., Eyre, D. W., Vihta, K.-D., House, T., Hay, J., Bell, J. I., Newton, J. N., Farrar, J., Crook, D., Cook, D., Rourke, E., Studley, R., Peto, T. E. A., Diamond, I., & Walker, A. S. (2021). Effect of delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. Nature Medicine, 27(12), 2127–2135. https://​doi.​org/​10.​1038/​s41591-021-01548-7CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Ministero della Salute. (2021). Aggiornamento delle indicazioni sulla somministrazione di dosi addizionali e di dosi “booster” nell’ambito della campagna di vaccinazione anti SARS-CoV-2/COVID-19. Ordinanza n.45886, 8 ottobre 2021. Ministero della Salute. (2021). Aggiornamento delle indicazioni sulla somministrazione di dosi addizionali e di dosi “booster” nell’ambito della campagna di vaccinazione anti SARS-CoV-2/COVID-19. Ordinanza n.45886, 8 ottobre 2021.
14.
Zurück zum Zitat Ripabelli, G., Tamburro, M., Buccieri, N., Adesso, C., Caggiano, V., Cannizzaro, F., Di Palma, M. A., Mantuano, G., Montemitro, V. G., Natale, A., Rodio, L., & Sammarco, M. L. (2022). Active surveillance of adverse events in healthcare workers recipients after vaccination with COVID-19 BNT162b2 vaccine (Pfizer-BioNTech, Comirnaty): A cross-sectional study. Journal of Community Health, 47(2), 211–225. https://doi.org/10.1007/s10900-021-01039-3CrossRefPubMed Ripabelli, G., Tamburro, M., Buccieri, N., Adesso, C., Caggiano, V., Cannizzaro, F., Di Palma, M. A., Mantuano, G., Montemitro, V. G., Natale, A., Rodio, L., & Sammarco, M. L. (2022). Active surveillance of adverse events in healthcare workers recipients after vaccination with COVID-19 BNT162b2 vaccine (Pfizer-BioNTech, Comirnaty): A cross-sectional study. Journal of Community Health, 47(2), 211–225. https://​doi.​org/​10.​1007/​s10900-021-01039-3CrossRefPubMed
15.
Zurück zum Zitat Bar-On, Y. M., Goldberg, Y., Mandel, M., Bodenheimer, O., Freedman, L., Kalkstein, N., Mizrahi, B., Alroy-Preis, S., Ash, N., Milo, R., & Huppert, A. (2021). Protection of BNT162b2 vaccine booster against Covid-19 in Israel. The New England Journal of Medicine, 385(15), 1393–1400. https://doi.org/10.1056/NEJMoa2114255CrossRefPubMed Bar-On, Y. M., Goldberg, Y., Mandel, M., Bodenheimer, O., Freedman, L., Kalkstein, N., Mizrahi, B., Alroy-Preis, S., Ash, N., Milo, R., & Huppert, A. (2021). Protection of BNT162b2 vaccine booster against Covid-19 in Israel. The New England Journal of Medicine, 385(15), 1393–1400. https://​doi.​org/​10.​1056/​NEJMoa2114255CrossRefPubMed
16.
Zurück zum Zitat Gilboa, M., Mandelboim, M., Indenbaum, V., Lustig, Y., Cohen, C., Rahav, G., Asraf, K., Amit, S., Jaber, H., Nemet, I., Kliker, L., Bar-Haim, E., Mendelson, E., Doolman, R., Rubin, C., Regev-Yochay, G., & Kreiss, Y. (2022). Early immunogenicity and safety of the third dose of BNT162b2 mRNA Covid-19 vaccine among adults older than 60 years: Real-world experience. The Journal of Infectious Diseases, 225(5), 785–792. https://doi.org/10.1093/infdis/jiab584CrossRefPubMed Gilboa, M., Mandelboim, M., Indenbaum, V., Lustig, Y., Cohen, C., Rahav, G., Asraf, K., Amit, S., Jaber, H., Nemet, I., Kliker, L., Bar-Haim, E., Mendelson, E., Doolman, R., Rubin, C., Regev-Yochay, G., & Kreiss, Y. (2022). Early immunogenicity and safety of the third dose of BNT162b2 mRNA Covid-19 vaccine among adults older than 60 years: Real-world experience. The Journal of Infectious Diseases, 225(5), 785–792. https://​doi.​org/​10.​1093/​infdis/​jiab584CrossRefPubMed
17.
Zurück zum Zitat Tenforde, M. W., Patel, M. M., Gaglani, M., Ginde, A. A., Douin, D. J., Talbot, H. K., Casey, J. D., Mohr, N. M., Zepeski, A., McNeal, T., Ghamande, S., Gibbs, K. W., Files, D. C., Hager, D. N., Shehu, A., Prekker, M. E., Erickson, H. L., Gong, M. N., Mohamed, A.,…IVY Network. (2022). Effectiveness of a third dose of Pfizer-BioNTech and moderna vaccines in preventing COVID-19 hospitalization among immunocompetent and immunocompromised adults—United States, August-December 2021. MMWR Morbidity and Mortality Weekly Report, 71(4), 118–1124. https://doi.org/10.15585/mmwr.mm7104a2CrossRefPubMed Tenforde, M. W., Patel, M. M., Gaglani, M., Ginde, A. A., Douin, D. J., Talbot, H. K., Casey, J. D., Mohr, N. M., Zepeski, A., McNeal, T., Ghamande, S., Gibbs, K. W., Files, D. C., Hager, D. N., Shehu, A., Prekker, M. E., Erickson, H. L., Gong, M. N., Mohamed, A.,…IVY Network. (2022). Effectiveness of a third dose of Pfizer-BioNTech and moderna vaccines in preventing COVID-19 hospitalization among immunocompetent and immunocompromised adults—United States, August-December 2021. MMWR Morbidity and Mortality Weekly Report, 71(4), 118–1124. https://​doi.​org/​10.​15585/​mmwr.​mm7104a2CrossRefPubMed
18.
Zurück zum Zitat Barda, N., Dagan, N., Cohen, C., Hernán, M. A., Lipsitch, M., Kohane, I. S., Reis, B. Y., & Balicer, R. D. (2021). Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: An observational study. The Lancet, 398(10316), 2093–2100. https://doi.org/10.1016/S0140-6736(21)02249-2CrossRef Barda, N., Dagan, N., Cohen, C., Hernán, M. A., Lipsitch, M., Kohane, I. S., Reis, B. Y., & Balicer, R. D. (2021). Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: An observational study. The Lancet, 398(10316), 2093–2100. https://​doi.​org/​10.​1016/​S0140-6736(21)02249-2CrossRef
19.
Zurück zum Zitat Nicolay, N., Innocenti, F., Beauté, J., Učakar, V., GrgičVitek, M., Poukka, E., Hannila-Handelberg, T., Gauci, C., Melillo, T., Georgakopoulou, T., Jarkovsky, J., Slezak, P., Delgado-Sanz, C., Olmedo-Lucerón, C., Suija, H., Liausediene, R., O’Lorcain, P., Murphy, N., Peralta-Santos, A.,…Ravasi, G. (2021). Initial assessment of the COVID-19 vaccination’s impact on case numbers, hospitalisations and deaths in people aged 80 years and older, 15 EU/EEA countries, December 2020 to May 2021. Eurosurveillance, 6(48), 2101030. https://doi.org/10.2807/1560-7917.ES.2021.26.48.2101030CrossRef Nicolay, N., Innocenti, F., Beauté, J., Učakar, V., GrgičVitek, M., Poukka, E., Hannila-Handelberg, T., Gauci, C., Melillo, T., Georgakopoulou, T., Jarkovsky, J., Slezak, P., Delgado-Sanz, C., Olmedo-Lucerón, C., Suija, H., Liausediene, R., O’Lorcain, P., Murphy, N., Peralta-Santos, A.,…Ravasi, G. (2021). Initial assessment of the COVID-19 vaccination’s impact on case numbers, hospitalisations and deaths in people aged 80 years and older, 15 EU/EEA countries, December 2020 to May 2021. Eurosurveillance, 6(48), 2101030. https://​doi.​org/​10.​2807/​1560-7917.​ES.​2021.​26.​48.​2101030CrossRef
20.
Zurück zum Zitat Thompson, M. G., Natarajan, K., Irving, S. A., Rowley, E. A., Griggs, E. P., Gaglani, M., Klein, N. P., Grannis, S. J., DeSilva, M. B., Stenehjem, E., Reese, S. E., Dickerson, M., Naleway, A. L., Han, J., Konatham, D., McEvoy, C., Rao, S., Dixon, B. E., Dascomb, K.,…Ong, T. C. (2022). Effectiveness of a third dose of mRNA vaccines against COVID-19-associated emergency department and urgent Care encounters and hospitalizations among adults during periods of delta and omicron variant predominance—VISION network, 10 states, August 2021-January 2022. MMWR Morbidity and Mortality Weekly Report, 71(4), 139–145. https://doi.org/10.15585/mmwr.mm7104e3CrossRefPubMed Thompson, M. G., Natarajan, K., Irving, S. A., Rowley, E. A., Griggs, E. P., Gaglani, M., Klein, N. P., Grannis, S. J., DeSilva, M. B., Stenehjem, E., Reese, S. E., Dickerson, M., Naleway, A. L., Han, J., Konatham, D., McEvoy, C., Rao, S., Dixon, B. E., Dascomb, K.,…Ong, T. C. (2022). Effectiveness of a third dose of mRNA vaccines against COVID-19-associated emergency department and urgent Care encounters and hospitalizations among adults during periods of delta and omicron variant predominance—VISION network, 10 states, August 2021-January 2022. MMWR Morbidity and Mortality Weekly Report, 71(4), 139–145. https://​doi.​org/​10.​15585/​mmwr.​mm7104e3CrossRefPubMed
Metadaten
Titel
A SARS-CoV-2 Outbreak Among Nursing Home Residents Vaccinated with a Booster Dose of mRNA COVID-19 Vaccine
verfasst von
Giancarlo Ripabelli
Michela Lucia Sammarco
Giovanni Rezza
Antonio D’Amico
Roberta De Dona
Mariagrazia Iafigliola
Albino Parente
Nicandro Samprati
Arturo Santagata
Carmen Adesso
Anna Natale
Michela Anna Di Palma
Fabio Cannizzaro
Cosimo Dentizzi
Paola Stefanelli
Manuela Tamburro
Publikationsdatum
25.03.2022
Verlag
Springer US
Schlagwort
COVID-19
Erschienen in
Journal of Community Health / Ausgabe 4/2022
Print ISSN: 0094-5145
Elektronische ISSN: 1573-3610
DOI
https://doi.org/10.1007/s10900-022-01082-8

Weitere Artikel der Ausgabe 4/2022

Journal of Community Health 4/2022 Zur Ausgabe